The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Cited by
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00946-7 · Cited by 1,273
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15081 · Cited by 992
“47) have begun.”
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 804
Ferroptosis in cancer and cancer immunotherapy
Zhao, L., Zhou, X., Xie, F., Zhang, L., Yan, H., Huang, J., Zhang, C., Zhou, F., Chen, J., & Zhang, L. (2022) · Cancer Communications · doi:10.1002/cac2.12250 · Cited by 684
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18570-x · Cited by 553
Resistance to PD1/PDL1 checkpoint inhibition
O'Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 572
Immunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
Tang, H., Liang, Y., Anders, R. A., Taube, J. M., Qiu, X., Mulgaonkar, A., Liu, X., Harrington, S. M., Guo, J., Xin, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96061 · Cited by 524
Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 523
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 504
Kwok, G., Yau, T. C. C., Chiu, J. W., Tse, E., & Kwong, Y.-L. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1199310 · Cited by 498
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2018) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 433
Zhou, G., Sprengers, D., Boor, P. P. C., Doukas, M., Schutz, H., Mancham, S., Pedroza-Gonzalez, A., Polak, W. G., de Jonge, J., Gaspersz, M., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.017 · Cited by 412
Zumla, A., Rao, M., Wallis, R. S., Kaufmann, S. H. E., Rustomjee, R., Mwaba, P., Vilaplana, C., Yeboah-Manu, D., Chakaya, J., Ippolito, G., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00078-5 · Cited by 402
Sahin, I. H., Akce, M., Alese, O., Shaib, W., Lesinski, G. B., El-Rayes, B., & Wu, C. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0599-y · Cited by 393
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Understanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
Muñoz-Fontela, C., Mandinova, A., Aaronson, S. A., & Lee, S. W. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.99 · Cited by 341
Carey, C. D., Gusenleitner, D., Lipschitz, M., Roemer, M. G. M., Stack, E. C., Gjini, E., Hu, X., Redd, R., Freeman, G. J., Neuberg, D., et al. (2017) · Blood · doi:10.1182/blood-2017-03-770719 · Cited by 323
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
Zelle-Rieser, C., Thangavadivel, S., Biedermann, R., Brunner, A., Stoitzner, P., Willenbacher, E., Greil, R., & Jöhrer, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0345-3 · Cited by 319
Biomarkers of response to PD-1/PD-L1 inhibition
Maleki Vareki, S., Garrigós, C., & Duran, I. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.001 · Cited by 318
T-cell Dysfunction in Glioblastoma: Applying a New Framework
Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A., & Fecci, P. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0047 · Cited by 315
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Kürten, C. H. L., Kulkarni, A., Cillo, A. R., Santos, P. M., Roble, A. K., Onkar, S., Reeder, C., Lang, S., Chen, X., Duvvuri, U., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27619-4 · Cited by 293
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Lu, Y.-C., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 279
Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2
Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., Zehnder, A., Ohgami, R., Kulkarni, S., Armstrong, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3370 · Cited by 277
Estrogen Receptor Signaling in the Immune System
Chakraborty, B., Byemerwa, J., Krebs, T., Lim, F., Chang, C.-Y., & McDonnell, D. P. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac017 · Cited by 263
PD-1 expression on dendritic cells suppresses CD8+T cell function and antitumor immunity
Lim, T. S., Chew, V., Sieow, J. L., Goh, S., Yeong, J. P.-S., Soon, A. L., & Ricciardi-Castagnoli, P. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1085146 · Cited by 184
Azzaoui, I., Uhel, F., Rossille, D., Pangault, C., Dulong, J., Le Priol, J., Lamy, T., Houot, R., Le Gouill, S., Cartron, G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662783 · Cited by 168
Tu, L., Guan, R., Yang, H., Zhou, Y., Hong, W., Ma, L., Zhao, G., & Yu, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.32785 · Cited by 167
CD8+ T cell exhaustion and cancer immunotherapy
Wang, Q., Qin, Y., & Li, B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216043 · Cited by 155
Creatine uptake regulates CD8 T cell antitumor immunity
Di Biase, S., Ma, X., Wang, X., Yu, J., Wang, Y.-C., Smith, D. J., Zhou, Y., Li, Z., Kim, Y. J., Clarke, N., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182044 · Cited by 132
“In particular, the PD-1hiTim3hiLAG-3hi tumor-infiltrating CD8 T cells, which are considered to be the most “exhausted,” expressed the highest levels of CrT, suggesting that these cells may also benefit the most from creatine supplementation treatment (Fig. S1 K; Nguyen and Ohashi, 2015; Wherry and Kurachi, 2015).”
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant
Pascolutti, R., Sun, X., Kao, J., Maute, R. L., Ring, A. M., Bowman, G. R., & Kruse, A. C. (2016) · Structure · doi:10.1016/j.str.2016.06.026 · Cited by 102
“Of the two PD-1 ligands, PD-L1 is thought to be the primary mediator of cancer immune evasion, although PD-L2 may play a role in certain cases (Nguyen and Ohashi, 2015).”
BackgroundProbiotic species in the modulation of the anticancer immune response
Marinelli, L., Tenore, G. C., & Novellino, E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.007 · Cited by 64
Qiu, M.-Z., Wang, C., Wu, Z., Zhao, Q., Zhao, Z., Huang, C.-Y., Wu, W., Yang, L.-Q., Zhou, Z.-W., Zheng, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01622-1 · Cited by 58
Hatfield, S. M., & Sitkovsky, M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052934 · Cited by 31
Metadata
- Authors
- Nguyen, L. T., & Ohashi, P. S.
- Venue
- Nature Reviews Immunology
- Published
- 2014-12-23
- Volume
- 15
- Issue
- 1
- Pages
- 45-56
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2130030995
- Cited by
- 627
- References
- 127
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.